PEIJIA-B (09996) has successfully completed the first compassionate treatment using the TaurusTrioTM TAVR system in Hong Kong, China.
Peijia Medical-B (09996) announced that the board of directors of the company is pleased to announce that recently, the group has used for the treatment of symptomatic...
PEIJIA-B (09996) announces that the company's Board of Directors is pleased to announce that the company's product TaurusTrio, used for the treatment of symptomatic severe aortic valve regurgitation (AR), has successfully completed the first compassionate use case in Hong Kong, China.
In January 2024, the company completed patient enrollment in the multicenter registered clinical trial for the TaurusTrio TAVR system in China. Follow-up assessments in the subsequent phases are currently ongoing. The company anticipates commercializing this product in China upon regulatory approval to meet the unmet needs of a large number of AR patients.
Related Articles

Industrial: Hong Kong stock market sentiment index has reached the bottom area.

"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"

Guosen: RWA welcomes the era of strict supervision.
Industrial: Hong Kong stock market sentiment index has reached the bottom area.

"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"

Guosen: RWA welcomes the era of strict supervision.

RECOMMEND

Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026

Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026

Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026


